Targeted Therapies for the Treatment of Breast Cancer
Last Modified: May 11, 2005
Conference Dates: July 6-9, 2005
Conference Location: Dana Point, California
Sponsoring Group: The CBCE (The Center for Biomedical Continuing Education)
Conference Web Page URL: www.thecbce.com/currentactivities.asp
- Statement of Need: Rationally designed target-based therapies beyond those targeting the estrogen receptor are increasingly important in breast cancer treatments.
- Trastuzumab has established itself in HER2+ breast cancer, and its use in the adjuvant and neoadjuvant settings is currently being assessed.
- Other novel agents that target other ErbB receptors include the small-molecule epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib; these agents are now being evaluated in breast cancer.
- Targeted therapies against the vascular endothelial growth factor (VEGF) pathway, such as bevacizumab and lapatinib, are effective in other malignancies and are also entering the breast cancer arena.
- Additional agents target downstream signaling molecules that modulate progression through the cell cycle and resistance to apoptosis, including the mTOR inhibitor RAD001.
- This program will provide physicians with an overview of the most recent advances in the field of targeted therapeutics for the treatment of breast cancer.
- Compare the efficacy and safety of various estrogen receptor–targeted therapies.
- Compare and contrast signal transduction inhibitors currently under evaluation for treatment of breast cancer.
- Discuss the efficacy of HER-targeted inhibitors under investigation for the treatment of breast cancer, and relate the current status of trastuzumab-based clinical trials.
- Evaluate the efficacy and safety of novel agents designed to restore the apoptotic pathway in tumor cells for treatment of your patients with breast cancer.
- Evaluate recent clinical data on the use of angiogenesis inhibitors—alone and in combination regimens—in the treatment of breast cancer.
Who Should Attend: This activity is intended for medical oncologists and other physicians interested in the treatment of breast cancer.
Conference Agenda: Please see www.thecbce.com/currentactivities.asp for the current agenda.
Registration Information: * A limited number of Scholarships are available for fellows. For consideration and further information, please contact Zack Lentz. REGISTRATION FEES: The registration fee covers participation at all conference sessions, meeting materials, and food functions per the agenda.
- Physician (in practice or academic research): $395
- Fellow, nurse, and other health care professionals (in practice or academic research): $195
- Industry/All others: $1,895 (This category is defined by the CBCE as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.)
Conference Fees: Please see website for further information
Continuing Education: Yes
Miscellany: The CBCE™ (The Center for Biomedical Continuing Education) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians. The CBCE designates this educational activity for a maximum of 15.75 category 1 credits towards the AMA Physician’s Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity. Participants who submit CME Request for Credit and Evaluation Forms will receive their CME certificate 4-6 weeks after the activity.